Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exatecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exatecan SCHEMBL7255477 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL29351332 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL31615015 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL29601765 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL23471938 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL25349032 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL7249645 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL26320 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL7163616 | 0.99 | TOP1 (0.59) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL6047672 | 0.99 | TOP1 (0.59) | TOP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137796-A1 | PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2026-05-21 | — | — | US | claimed |
| EP-4740956-A1 | PHARMACEUTICAL COMBINATION FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4739713-A1 | ANTI-TROP2 ANTIBODIES | Agency for Science, Technology and Research (SG) | 2026-05-13 | — | — | EP | claimed |
| CN-122029199-A | Cysteine engineered antibodies and immunoconjugates | 信达生物制药(苏州)有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2026090567-A1 | FLT3-BINDING ANTIBODIES AND METHODS OF USE THEREOF | Antharis Therapeutics Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090578-A1 | CDH17-BINDING ANTIBODIES AND METHODS OF USE THEREOF | Antharis Therapeutics Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260115303-A1 | CDH17-BINDING ANTIBODIES AND METHODS OF USE THEREOF | ANTHARIS THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4725968-A1 | ANTI-GPC3 ANTIBODY OR ANTIGEN-BINDING FRAGMENT AND USE THEREOF | Salubris (Chengdu) Biotech Co., Ltd. (CN) | 2026-04-15 | — | — | EP | claimed |
| EP-4725508-A1 | LIGAND-DRUG CONJUGATE HAVING FREE PAYLOAD RECOVERY UNIT | RemeGen Co., Ltd. (CN) | 2026-04-15 | — | — | EP | claimed |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | HALOZYME, INC. (US) | 2026-03-12 | — | — | US | claimed |
| US-20030148931-A1 | Pharmaceutical compositions containing dds compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-07 | — | — | US | claimed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | claimed |
| US-20030109460-A1 | Medicinal composition containing camptothecin derivative and ph regulating agent | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-12 | — | — | US | claimed |
| EP-1310254-A1 | MEDICINAL COMPOSITIONS CONTAINING CAMPTOTHECIN DERIVATIVE AND PH REGULATING AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-14 | — | — | EP | claimed |
| EP-1308171-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DDS COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-07 | — | — | EP | claimed |
| EP-1298145-A1 | DDS COMPOUND AND PROCESS FOR THE PREPARATION THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-02 | — | — | EP | claimed |
| US-6436912-B1 | DRUG COMPLEX COMPRISING CARBOXY(C.SUB.1-4)ALKYLDEXTRAN POLYALCOHOL AND RESIDUE OF DRUG COMPOUND BOUND TO EACH OTHER WITH SPACER COMPRISING AMINO ACID OR SPACER COMPRISING PEPTIDE-BONDED 2 TO 8 AMINO ACIDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-08-20 | — | — | US | claimed |
| EP-1155702-A1 | DDS COMPOUNDS AND METHOD FOR ASSAYING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-11-21 | — | — | EP | claimed |
| EP-1080732-A1 | DRUG COMPOSITES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | claimed |
| EP-0916348-A1 | DRUG COMPLEXES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | TOP1 304/4885MEN1 3082/4885KMT2A 2754/4885 |
| US-20260115303-A1 | CDH17-BINDING ANTIBODIES AND METHODS OF USE THEREOF | CDH1, H1-3, H1-2 | TOP1 1943/4885MEN1 181/4885KMT2A 983/4885 |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | CD22, CD2, CD44 | TOP1 1901/4885MEN1 800/4885KMT2A 1897/4885 |
| US-20260137796-A1 | PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | TOP2B, TOP1, TOP2A | TOP1 2/4885MEN1 3308/4885KMT2A 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.